MedTrace Logo

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

NCT00372996 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2015-10-28

Study results available
· View outcomes & findings →

Summary

To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer

Conditions

  • Breast Neoplasms

Interventions

DRUG

CP-751,871

CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.

DRUG

exemestane

Exemestane given at 25 mg orally once a day.

DRUG

exemestane

Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity

DRUG

Fulvestrant

Used for salvage therapy and administered according to the local label and standard clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2012-09-30
Completion
2014-06-30

Countries

  • United States
  • Argentina
  • Belgium
  • Brazil
  • Canada
  • Italy
  • Netherlands
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00372996 on ClinicalTrials.gov